Latest News & Features
Pharma
Dispute hinges on clauses set out in decade-old settlement and licensing agreement | Federal Circuit unpersuaded by arguments suggesting that a federal court erred in denying a preliminary injunction. 4 January 2024
Americas
California-based drugmaker lost Hatch-Waxman Act case after judge ruled it had failed to show patent infringement | Corcept CEO ‘confident’ decision will be reversed on appeal. 4 January 2024
Pharma
District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents. 2 January 2024
Pharma
Life science attorneys should see some notable developments relating to artificial intelligence, patent eligibility and the Fintiv rule, write Manita Rawat and Alexander Stein of Morgan Lewis. 2 January 2024
article
Managing partner oversees a varied range of global patent portfolios, often acting as the ‘in-house’ attorney for multinational clients. 2 January 2024
Biotech
Mark Hatch-Miller, who led the trial team at Susman for Globus, tells Sarah Speight how this spinal implant patent dispute, brought by a Johns Hopkins neurosurgeon, was a “heavy lift”. 21 December 2023
Pharma
CureVac suffers a blow following a favourable earlier opinion delivered by the German Federal Patent Court | Decision invalidates a patent related to mRNA tech. 21 December 2023
Biotech
Medical device company wins eight-day jury trial in spinal implant patent dispute | Johns Hopkins neurosurgeon claimed Globus Medical directly infringed multiple patents in US | Susman Godfrey | Fish & Richardson. 19 December 2023
Pharma
The Biden administration’s proposals target price gouging triggers resistance | The move, which includes the consideration of march-in rights for taxpayer-funded drugs, may ‘jeopardise collaborative partnerships and hinder innovation. 19 December 2023
Biotech
Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines. 14 December 2023